Fig. 3.
ERBB2 mutants found in lung and breast cancer form reduction-sensitive dimers that exhibit diminished C-terminal tail phosphorylation. (A) Immunoblot analysis of ERBB2 protein and tyrosine 1221/1222 phosphorylation state on lysates of NIH 3T3 expressing ERBB2 extracellular domain mutations. (B) Immunoblot analysis of ERBB2 dimers trapped by nonreducing SDS/PAGE. pBp, pBabe puro vector; WT, wild-type ERBB2.